ROCO
4102
Market cap24mUSD
Oct 08, Last price
18.80TWD
1D
0.80%
1Q
-8.29%
Jan 2017
9.94%
IPO
12.51%
Name
Yung Zip Chemical Ind Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yung Zip Chemical Ind. Co., Ltd. is a global provider specializing in the manufacture of essential pharmaceutical components. The company supplies active pharmaceutical ingredients (APIs), their intermediate precursors, and various specialty chemicals to markets around the world. Their diverse product portfolio includes a wide array of therapeutic agents addressing conditions such as hypertension, iron overload, inflammation, pain, fever, fungal infections, schizophrenia, blood clotting issues, genital herpes outbreaks, and sleep disorders (hypnotics and sedatives). In addition to these core offerings, Yung Zip also provides pharmaceutical excipients, such as sodium starch glycolate, and offers bespoke research, development, and manufacturing services. The company, established in 1978, is headquartered in Taichung, Taiwan.
Key people
Ching Hwang Lin
Chairman of the Board, General Manager, Corporate Governance Officer · since 2024
Shuqin Xie
Head of Finance · since 2007
Yuru Li
General Manager · since 2025
Yandao Wu
Head of Accounting, Corporate Governance Officer · since 2025
Director · since 2025
Hongwen Jiang
Director · since 2007
Director · since 2022
Fang Chen Lee
Director · since 2018
Director · since 2022
Tingjun Lin
Director · since 2025
Yangzong Cai
Independent Director · since 2016
Shiuh-Tzung Liu
Independent Director · since 2025
Independent Director · since 2019
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||